JP2025513501A - 凍結乾燥組成物 - Google Patents
凍結乾燥組成物 Download PDFInfo
- Publication number
- JP2025513501A JP2025513501A JP2024562210A JP2024562210A JP2025513501A JP 2025513501 A JP2025513501 A JP 2025513501A JP 2024562210 A JP2024562210 A JP 2024562210A JP 2024562210 A JP2024562210 A JP 2024562210A JP 2025513501 A JP2025513501 A JP 2025513501A
- Authority
- JP
- Japan
- Prior art keywords
- aqueous composition
- pharma
- acceptable salt
- reconstituted
- rilpivirine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333557P | 2022-04-22 | 2022-04-22 | |
| US63/333,557 | 2022-04-22 | ||
| EP22173920.4 | 2022-05-17 | ||
| EP22173920 | 2022-05-17 | ||
| PCT/EP2023/060686 WO2023203255A1 (en) | 2022-04-22 | 2023-04-24 | Freeze dried compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513501A true JP2025513501A (ja) | 2025-04-24 |
| JP2025513501A5 JP2025513501A5 (cg-RX-API-DMAC7.html) | 2026-05-08 |
Family
ID=86330122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024562210A Pending JP2025513501A (ja) | 2022-04-22 | 2023-04-24 | 凍結乾燥組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250275967A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4511007A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025513501A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119403545A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3249784A1 (cg-RX-API-DMAC7.html) |
| TW (2) | TW202406551A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023203257A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| PT3366278T (pt) | 2006-06-23 | 2024-10-21 | Janssen Sciences Ireland Unlimited Co | Suspensões aquosas de tmc278 |
| BRPI0715113A2 (pt) * | 2006-07-26 | 2013-06-04 | Sandoz Ag Sandoz Sa Sandoz Ltd | formulaÇço de caspofungina |
| AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| GB2513060B (en) * | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| HRP20201241T1 (hr) * | 2011-04-15 | 2020-11-27 | Janssen Pharmaceutica N.V. | Nanosuspenzije lijeka osušene zamrzavanjem |
| WO2018013673A1 (en) * | 2016-07-13 | 2018-01-18 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
| WO2022109555A1 (en) | 2020-11-17 | 2022-05-27 | Janssen Sciences Ireland Unlimited Company | Treatment or prevention of hiv infection |
-
2023
- 2023-04-24 WO PCT/EP2023/060688 patent/WO2023203257A1/en not_active Ceased
- 2023-04-24 JP JP2024562210A patent/JP2025513501A/ja active Pending
- 2023-04-24 TW TW112115224A patent/TW202406551A/zh unknown
- 2023-04-24 TW TW112115222A patent/TW202408580A/zh unknown
- 2023-04-24 EP EP23722287.2A patent/EP4511007A1/en active Pending
- 2023-04-24 CA CA3249784A patent/CA3249784A1/en active Pending
- 2023-04-24 US US18/858,037 patent/US20250275967A1/en active Pending
- 2023-04-24 CN CN202380048657.2A patent/CN119403545A/zh active Pending
- 2023-04-24 WO PCT/EP2023/060686 patent/WO2023203255A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4511007A1 (en) | 2025-02-26 |
| WO2023203255A1 (en) | 2023-10-26 |
| CN119403545A (zh) | 2025-02-07 |
| WO2023203257A1 (en) | 2023-10-26 |
| US20250275967A1 (en) | 2025-09-04 |
| TW202408580A (zh) | 2024-03-01 |
| CA3249784A1 (en) | 2023-10-26 |
| TW202406551A (zh) | 2024-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2723371B1 (en) | Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same | |
| JP7150804B2 (ja) | プラミノーゲンを含む医薬組成物及びその使用 | |
| US20090298743A1 (en) | Hydrophobic compositions containing reconstitution enhancer | |
| KR20090023703A (ko) | Tmc278의 수성 현탁제 | |
| JP2007512266A (ja) | Egf受容体に対する抗体を含む医薬製剤 | |
| JP6869255B2 (ja) | 凍結医薬製剤およびその使用 | |
| US20250275967A1 (en) | Freeze dried compositions | |
| JP2025513502A (ja) | 液体組成物 | |
| CN116744903A (zh) | 包含二苯基吡嗪衍生物的药物组合物 | |
| JP2023549837A (ja) | 疾患又は障害の治療又は予防 | |
| US20130131089A1 (en) | Dosage forms of elinogrel and methods of injectable administration thereof | |
| JP2024540465A (ja) | 溶解試験 | |
| CA3268292A1 (en) | LONG-ACTING FORMULAS | |
| WO2024068693A1 (en) | Long-acting formulations | |
| TW202408526A (zh) | 治療或預防hiv感染(一) | |
| WO2011137459A1 (en) | Dosage forms of elinogrel and methods of injectable administration thereof | |
| CN116437923A (zh) | Hiv感染的治疗或预防 | |
| HK1175984B (en) | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260424 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260424 |